On April 13, 2026, IDEAYA Biosciences announced positive results from its Phase 2/3 trial of darovasertib and crizotinib for metastatic uveal melanoma, showing a significant median progression-free survival (PFS) improvement of 6.9 months compared to 3.1 months for existing therapies. The trial included 313 patients, with a notable reduction of disease progression risk by 58%.